Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes|
|Citation:||Diabetes Care, 2016; 39(4):511-517|
|Publisher:||American Diabetes Association|
|Tongzhi Wu, Tanya J. Little, Michelle J. Bound, Malcolm Borg, Xiang Zhang, Carolyn F. Deacon, Michael Horowitz, Karen L. Jones and Christopher K. Rayner|
|Abstract:||Objective: Nutrient "preloads" given before meals can attenuate postprandial glycemic excursions, at least partly by slowing gastric emptying and stimulating secretion of the incretins (i.e., glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]). This study was designed to evaluate whether a protein preload could improve the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin to increase incretin concentrations, slow gastric emptying, and lower postprandial glycemia in type 2 diabetes. Research design and methods: Twenty-two patients with type 2 diabetes treated with metformin were studied on four occasions, receiving either 50 mg vildagliptin (VILD) or placebo (PLBO) on both the evening before and the morning of each study day. The latter dose was followed after 60 min by a preload drink containing either 25 g whey protein (WHEY) or control flavoring (CTRL), and after another 30 min by a (13)C-octanoate-labeled mashed potato meal. Plasma glucose and hormones, and gastric emptying, were evaluated. Results: Compared with PLBO/CTRL, PLBO/WHEY reduced postprandial peak glycemia, increased plasma insulin, glucagon, and incretin hormones (total and intact), and slowed gastric emptying, whereas VILD/CTRL reduced both the peak and area under the curve for glucose, increased plasma intact incretins, and slowed gastric emptying but suppressed plasma glucagon and total incretins (P < 0.05 each). Compared with both PLBO/WHEY and VILD/CTRL, VILD/WHEY was associated with higher plasma intact GLP-1 and GIP, slower gastric emptying, and lower postprandial glycemia (P < 0.05 each). Conclusions: In metformin-treated type 2 diabetes, a protein preload has the capacity to enhance the efficacy of vildagliptin to slow gastric emptying, increase plasma intact incretins, and reduce postprandial glycemia.|
|Keywords:||Humans; Diabetes Mellitus, Type 2; Metformin; Adamantane; Nitriles; Pyrrolidines; Gastric Inhibitory Polypeptide; Glucagon; Insulin; Blood Glucose; Hypoglycemic Agents; Double-Blind Method; Gastric Emptying; Postprandial Period; Aged; Middle Aged; Male; Glucagon-Like Peptide 1; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Whey Proteins; Vildagliptin|
|Rights:||© 2016 by the American Diabetes Association. Readers may use this article as long as thework is properly cited, the use is educational and not for profit, and the work is not altered.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.